Skip to main content

Table 1 Physicochemical characterization of silver nanoparticles

From: Repeated oral administration of low doses of silver in mice: tissue distribution and effects on central nervous system

AgNP aliquotb Before usea After usea
DLSc UV-Visd UV-Visd
Mean size (nm) Peak (nm) PdI λmax(nm) Hmax (A.U.) λmax(nm) Hmax (A.U.)
A 14.17 ± 0.23 15.30 ± 0.46 0.103 ± 0.047 391.89 ± 0.33 163.69 ± 0.60 391.44 ± 0.53 65.58 ± 12.39
B 14.46 ± 0.42 15.42 ± 0.66 0.129 ± 0.063 391.89 ± 0.33 161.35 ± 1.68 391.22 ± 0.44 130.52 ± 7.18
C 19.42 ± 7.42 15.21 ± 1.27 0.242 ± 0.063 391.00 ± 0.00 173.51 ± 4.62 391.00 ± 0.00 156.47 ± 2.51
D 14.59 ± 0.14 15.44 ± 0.96 0.159 ± 0.67 391.00 ± 0.00 161.31 ± 4.18 392.00 ± 0.00 158.61 ± 3.86
  1. a Quality control of AgNPs suspensions performed before the beginning of each dosing week (day −3, 4, 11, 18, “before use”), and at the end of each dosing week (day 4, 11, 18, 24, “after use”)
  2. bAliquots A, B, C, D were used in the 1st, 2nd, 3rd and 4th dosing week of the study, respectively
  3. cFor DLS analyses, the mean size of AgNPs is expressed in terms of hydrodynamic diameter and the maximum intensity peak is reported to describe samples having multimodal distributions, with the polydispersity index (pdI) providing a measure of particles uniformity
  4. dFor UV-Vis analyses, the maximum wavelength (λmax, i.e. the wavelength corresponding to the highest absorbance of AgNPs) as well as the maximum absorbance value (Hmax) are reported and are expressed as nanometer (nm) and arbitrary units (A.U.), respectively. The optical properties reported by the manufacturer NanoComposix (San Diego, USA) were: λmax 389 nm, Hmax 167.37